Elutia Inc. (NASDAQ:ELUT) director Guido J. Neels purchased a total of 30,000 shares of the company’s Class A Common Stock in two separate transactions, according to a Form 4 filing with the Securities and Exchange Commission.
The filing shows Neels acquired 15,000 shares on January 28, 2026, and another 15,000 shares on January 29, 2026. Both tranches were executed at an effective price of $1.06 per share. For the January 28 trade, the reported price range was between $1.00 and $1.10, while the January 29 transaction recorded prices between $1.03 and $1.10.
After these purchases, Neels holds 98,750 shares of Elutia directly.
Separately, Elutia released financial and operational updates that provide context to the insider activity. The company reported a 16% year-over-year increase in fourth-quarter revenue, bringing quarterly sales to about $3.3 million. At the same time, Elutia stated it had eliminated $26.9 million of secured debt.
However, Elutia’s third quarter of 2025 presented challenges: the company posted an earnings-per-share loss of $0.19, wider than analysts’ expected loss of $0.15, and revenue that missed expectations, coming in at $3.3 million versus an anticipated $7.4 million.
On the product front, Elutia is advancing an antibiotic-eluting biomatrix program and plans to submit an FDA filing for its NXT-41 base matrix in the first half of 2026.
Regulatory pressure is also present: Elutia received a notice from Nasdaq indicating non-compliance with market value and bid price rules. The company was given until June 2026 to regain compliance to avoid potential delisting.
In other corporate developments noted alongside Elutia’s updates, Elevra Lithium Ltd reported that all resolutions at its Annual General Meeting were approved, including the election of four directors.
The sequence of insider buying, recent revenue improvement, debt reduction and the planned FDA filing coexist with past quarterly misses and a Nasdaq compliance notice, outlining a mixed set of corporate indicators for investors and observers.